• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

L’Oréal buys Medik8, expanding its portfolio in anti-aging skincare market

by June 9, 2025
by June 9, 2025

French cosmetics behemoth L’Oréal is set to acquire Medik8, a British skincare brand renowned for its vitamin A-based anti-aging products.

The deal, announced Monday by Medik8’s current owner, UK-based private equity firm Inflexion, marks another strategic move by L’Oréal to deepen its presence in the rapidly expanding and highly lucrative dermatological skincare market.

While the financial terms of the acquisition were not disclosed, the addition of Medik8 is poised to enhance L’Oréal’s already formidable dermatological beauty division.

This unit, which boasts powerhouse brands such as CeraVe, La Roche-Posay, and SkinCeuticals, has been L’Oréal’s fastest-growing segment in recent years.

It achieved impressive revenues of 7 billion euros ($7.99 billion) last year, following nearly 10% growth from the year prior.

This division is also notable for having the highest profit margin among L’Oréal’s four main business units.

The surge in consumer interest for science-backed skincare products has been a primary driver of this division’s success.

However, growth in this popular category has recently shown signs of moderation due to intensifying competition from both established players and emerging niche brands.

Strategic acquisition drive: reviving growth and expanding reach

L’Oréal executives have openly stated this year that the company is actively pursuing acquisitions as a strategy to revive flagging growth in certain areas and to further expand its global footprint.

The Medik8 purchase aligns perfectly with this objective.

This latest acquisition follows L’Oréal’s move in December to buy Korean skincare brand Dr.G and its acquisition of a minority stake in Oman-based luxury perfume house Amouage last year, signaling a consistent appetite for strategic additions to its portfolio.

Inflexion, the private equity firm selling Medik8, will retain a minority shareholding in the brand as part of the transaction.

According to a statement from Inflexion, “The partnership with L’Oreal will allow Medik8 to deepen its presence in existing markets and expand globally.”

This suggests a collaborative approach to nurturing Medik8’s future growth under L’Oréal’s ownership, leveraging the French giant’s extensive global distribution network and marketing prowess.

The post L’Oréal buys Medik8, expanding its portfolio in anti-aging skincare market appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Is full self-driving real or just hype? Promise, progress, and what’s on the road
next post
Europe markets open: stocks dip ahead of key US-China meeting; Chinese trade data disappoints

Related Posts

GO Residential REIT drops on debut after oversubscribed...

July 26, 2025

Meta to halt political ads in EU from...

July 26, 2025

Here’s why the Coursera stock price has surged...

July 26, 2025

What is Lip-Bu Tan doing for Intel stock...

July 26, 2025

LIDR stock skyrockets 150% after Nvidia deal, but...

July 26, 2025

London’s heat-stricken underground commute threatens its appeal

July 26, 2025

Oppenheimer says Carvana stock remains underestimated: find out...

July 26, 2025

Palantir stock hits all time high: here’s what...

July 26, 2025

What’s next for Paramount stock after FCC’s approval...

July 26, 2025

China proposes global AI body, pushes for Shanghai...

July 26, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • GO Residential REIT drops on debut after oversubscribed $410M IPO

    July 26, 2025
  • Meta to halt political ads in EU from October 2025 amid legal uncertainty

    July 26, 2025
  • Here’s why the Coursera stock price has surged and its next target

    July 26, 2025
  • What is Lip-Bu Tan doing for Intel stock that’s different from Pat Gelsinger?

    July 26, 2025
  • LIDR stock skyrockets 150% after Nvidia deal, but analysts are still cautious: here’s why

    July 26, 2025
  • London’s heat-stricken underground commute threatens its appeal

    July 26, 2025

Editors’ Picks

  • 1

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 2

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 5

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025
  • 6

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025
  • 7

    Elon Musk says federal employees must fill out productivity reports or resign

    February 23, 2025

Categories

  • Economy (1,964)
  • Editor's Pick (192)
  • Investing (185)
  • Stock (1,307)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

Here’s why the Nifty 50 Index may...

June 6, 2025

Apple stock price forecast: major concerns remain

March 5, 2025

US stocks open mixed: S&P 500, Nasdaq...

April 18, 2025